Staying on 2.5mg Mounjaro: what the evidence actually says

The myth: 2.5mg is a dose you can simply stay on if you feel fine there

The most common misconception about staying on 2.5mg Mounjaro is that feeling comfortable at that level is reason enough to remain there. It isn't. The 2.5mg dose was built into the titration schedule specifically to reduce the early nausea and digestive upset that can put people off the medicine entirely. Think of it as the first week of a new exercise routine: the gentle start exists to protect you, not to be the destination.

Tirzepatide's trial programme tested weight outcomes at 5mg, 10mg and 15mg maintenance doses. In SURMOUNT-1, participants on the 15mg dose achieved around 20–21% average body-weight reduction over 72 weeks, a result published in the New England Journal of Medicine and reviewed by NICE when it recommended tirzepatide for NHS use. The 2.5mg arm was not a maintenance arm. Staying there and expecting equivalent benefit is, bluntly, expecting the medicine to do something it was never tested to do at that dose.

If you're genuinely comfortable at 2.5mg with no side effects and wondering whether to move up, that's actually a good sign, it means titration is likely to go smoothly. Our guide on whether you can stay on 2.5mg of Mounjaro explores this question in detail for people weighing up exactly that decision. The Mounjaro overview on our treatment page covers how the full dose schedule works for people starting out.

When holding at 2.5mg can be the right call, temporarily

There are legitimate, clinician-supported reasons to pause titration at 2.5mg. Side effects that haven't settled (persistent nausea, frequent loose stools, fatigue that's affecting work) can justify holding a dose for an extra week or two rather than pushing through. That's not weakness; that's the prescriber applying the titration guidance sensibly.

Timing matters in practice too. If you're heading into surgery, your clinical team needs to know you're on tirzepatide, and pausing or delaying a dose increase around an elective procedure is often the right move. Illness that's affecting your ability to eat can also make a dose increase poorly timed. Even more ordinary things (a holiday that disrupts your routine, a stretch of work travel) sometimes mean your prescriber agrees a brief hold makes sense. The key word is 'temporary': the decision is made consciously, documented, and reviewed.

What's different from simply staying on 2.5mg indefinitely is that a planned, time-limited hold has a clinical reason and a plan to resume titration. Our page on how long people typically stay on 2.5mg Mounjaro covers the usual duration in more detail.

What your prescriber will actually look at

A prescriber reviewing whether it's appropriate for you to remain at 2.5mg will look at several things: how long you've been on it, what side effects you've experienced, any change in your weight, and whether there are clinical reasons to delay. They won't look at your comfort level alone, because comfort at the starter dose is expected, it's not an indicator that the dose is working therapeutically.

According to the NHS guidance on tirzepatide, the dose is normally increased every four weeks, with the prescriber's oversight, until you reach the highest dose that suits you. The word 'normally' carries weight: it acknowledges that variation exists, but under clinical supervision. Self-managing a decision to stay put, without a prescriber's input, is a different thing entirely, and not something a legitimate, regulated service would encourage.

If you're weighing the difference between staying at 2.5mg and moving to the next level, our page on Mounjaro 5mg sets out what that dose involves, and what the evidence says about how it compares to the starter. For anyone thinking about staying on 5mg Mounjaro longer-term, the same principles apply: the decision belongs with your prescriber, made with your full medical context in front of them.

The safety picture at 2.5mg, and what it doesn't protect you from

One thing worth being clear about: the side-effect profile of tirzepatide is broadly similar across doses, with gastrointestinal effects most common and typically most noticeable in the first few weeks or after a dose increase. Staying at 2.5mg long-term doesn't eliminate that risk profile; it just means you're at the lowest end of the therapeutic range. Pancreatitis, though uncommon, is a risk with GLP-1 and dual-agonist medicines at any dose, the MHRA has highlighted this, and the guidance is consistent: severe stomach pain that extends to the back, with or without vomiting, needs urgent medical attention regardless of which dose you're on.

If you're weighing up your options more broadly, our weight-loss treatment overview covers the full range of clinically supervised approaches available through a regulated UK pharmacy. And if a specific concern is making you hesitant to titrate (nausea at 2.5mg, for instance) what to expect with Mounjaro sickness at 5mg might answer the question sitting underneath this one.

Decisions about your dose are exactly the kind of thing our prescribers are here for. Speak to our prescribers through a free consultation if you'd like a clinical view on where you are in your treatment.